Mogamulizuab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor type 4 (CCR4).
It is given by injection into a vein.
Pregnancy category AU: C
Routes of administration
Antineoplastic agent
The most common side effects include rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection.
Mogamulizumab is indicated for the treatment of adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
Approved mogamulizumab for the treatment of relapsed or refractory mycosis fungoides and Sézary disease.
Mogamulizumab was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma.
Mogamulizumab is being explored as a treatment for HTLV-1–Associated Myelopathy: 79% of the patients showed reduction in spasticity and 32% showed decrease in motor disability.